Our key results of melanocytes and keratinocytes’ role in a feed-forward loop of cutaneous and systemic inflammatory processes, as well as the upregulation of LAG3 after treatment initiation, warrant a deeper investigation if these pharmacodynamics reflect the events that occur in the tumor microenvironment and possible therapeutic opportunities. This evidence concerns the gene LAG3 and neoplasm.